ICMJE DISCLOSURE FORM

Date: 29 NOV 2022

Your Name: Peter van der Meer

Manuscript Title: Een mutatie in het Phospholamban gen veroorzaakt een cardiomyopathie met veel impact

in Nederland.

Manuscript number (if known): D7274

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)		
4	All consists of family and a sub-				
1	All support for the present manuscript (e.g., funding,	IONIS	Grant support		
	provision of study materials,	Astra Zeneca	Grant support		
	medical writing, article processing charges, etc.)				
	No time limit for this item.				
	Time frame: past 36 months				
2	Grants or contracts from	Pfizer	Grant support		
	any entity (if not indicated	Pharma Nord	Grant support		
	in item #1 above).	Vifor Pharma	Grant support		
3	Royalties or licenses	None			
		_			
4	Consulting fees	Novo Nordisk	Paid to the institute		

		Novartis	Paid to the institute
		Vifor Pharma	Paid to the institute
		Pharmacosmos	Paid to the institute
		BridgeBio	Paid to the institute
5	Payment or honoraria for lectures, presentations,	None	
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert testimony	None	
	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or	None	
	Advisory Board		
10	Leadership or fiduciary role in other board, society,	None	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical	None	
	writing, gifts or other		
	services		
13	Other financial or non- financial interests	None	

Please place an "X" next to the following statement to indicate your agreement:

__X_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.